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Abstract
Access to quality-assured medical products improves health and save lives. However, one third of the world’s population
lacks timely access to quality-assured medicines while estimates indicate that at least 10% of medicine in low- and
middle-income countries (LMICs) are substandard or falsified (SF), costing approximately US$ 31 billion annually. National
regulatory authorities are the key government institutions that promote access to quality-assured medicines and combat
SF medical products but despite progress, regulatory capacity in LMICs is still insufficient. Continued and
increased investment in regulatory system strengthening (RSS) is needed. We have therefore reviewed existing
global normative documents and resources and engaged with our networks of global partners and stakeholders
to identify three critical challenges being faced by NRAs in LMICs that are limiting access to medical products
and impeding detection of and response to SF medicines. The challenges are; implementing value-added regulatory
practices that best utilize available resources, a lack of timely access to new, quality medical products, and limited
evidence-based data to support post-marketing regulatory actions. To address these challenges, we have identified
seven focused strategies; advancing and leveraging convergence and reliance initiatives, institutionalizing sustainability,
utilizing risk-based approaches for resource allocation, strengthening registration efficiency and timeliness,
strengthening inspection capacity and effectiveness, developing and implementing risk-based post-marketing quality
surveillance systems, and strengthening regulatory management of manufacturing variations. These proposed solutions
are underpinned by 13 focused recommendations, which we believe, if financed, technically supported and implemented,
will lead to stronger health system and as a consequence, positive health outcomes.
Keywords: Access to essential medicines, Substandard and falsified, Regulatory system strengthening
Background
Access1 to quality-assured medical products2 improves
health and saves lives. Nonetheless, according to the
World Health Organization (WHO), one-third of the
world’s population lacks timely access to quality assured
medicines [2]. Compounding this is the growing global
concern of substandard and falsified (SF) medical prod-
ucts, which WHO estimates constitute at least 10% of
medicines in low- and middle-income countries (LMICs)
and costs these countries US$ 31 billion annually [3].
Their prevalence jeopardizes patient safety, diminishes
confidence in health systems, increases treatment failure,
wastes resources, and contributes to antimicrobial resist-
ance [3, 4]. National regulatory authorities (NRAs) are the
key government institutions that promote access to quality
products and combat SF medicines, as called for by World
Health Assembly (WHA) Resolution 67.20 on regulatory
system strengthening (RSS) for medical products [5].
Considerable progress has been made to strengthen
medical product regulatory systems but capacity in many
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LMICs is still insufficient and indeed, sometimes a barrier
to access to medicines [6–9]. Increased investments in RSS
are therefore paramount to the attainment of mature regu-
latory systems. Recent global normative documents have
identified RSS priorities [5–7, 10, 11]. This paper builds
upon these documents and further defines the key RSS in-
vestment priorities needed to ensure timely access to new
medical products and to protect against SF medical prod-
ucts. To accomplish this, we identify three critical chal-
lenges LMICs currently face: –implementing value-added
regulatory practices that best utilize available resources; a
lack of timely access to new, quality medical products; and
limited evidence-based data to support post-marketing
regulatory actions. We also propose strategies and 13 fo-
cused recommendations (Table 1) for where investments
in regulatory systems are needed over the next decade to
achieve efficiencies, promote public confidence in health
systems, and ensure maximum public health impact.
Methods
The five normative documents [5–7, 10, 11] were iden-
tified by the authors through discussions with and rec-
ommendations from colleagues and partners working
in this field and our own collective experience and ex-
pertise. These sources, while not necessarily exhaustive,
represent a consolidated list of well-researched seminal
pieces published by various global health organizations
and global health experts within the last 10 years,
which center overarchingly on health system strength-
ening and access to medicines and identify important
and novel ideas and suggestions. We have sought to
build upon these existing resources by taking existing
best practices, relevant ideas and suggestions and pro-
viding an additional level of detail and identifying en-
tirely new recommendations through our experiences
and the review of additional, related literature. The
challenges, strategies and recommendations selected
Table 1 Summary of challenges, proposed strategies, and recommendations
Challenge Proposed Strategy No. Recommendation Recommendation
Typea
Implement value-added
regulatory practices that
utilize available resources
Advance and leverage
convergence and reliance
initiatives
1 Document and communicate current reliance and convergence
efforts and develop supporting infrastructure and tools to
facilitate implementation
Analytics
2 Strengthen capacity building networks Collaboration
Institutionalize sustainability 3 Define needed capacities in NRAs using the WHO global
benchmarking tool
Analytics
4 Establish stable and transparent financing mechanisms System
development
Utilize risk-based approaches for
resource allocation
5 Perform risk analysis and implement risk management Workforce
development
6 Develop systems to monitor and evaluate the impact of
risk-based approaches for resource allocation
Analytics
Timely access to new
quality-assured medical
products without
compromising safety
and efficacy
Strengthen registration
efficiency and timeliness
7 Establish and refine value-added registration processes,
resources, and systems
System
development
Collaboration
8 Build value-added technical capacity of assessors Workforce
development
Strengthen inspection capacity
and effectiveness
9 Enhance information sharing and use and reliance on
existing inspection resources
Collaboration
10 Build capacity of multi-disciplinary teams of inspectors Workforce
development
Limited evidence-based
data to support
post-marketing regulatory
action
Develop and implement
risk-based post-marketing
quality surveillance systems
11 Establish recognition of the value for risk-based post-marketing
quality surveillance throughout the supply chain
System
development
12 Develop and implement risk-based post-marketing quality
surveillance programs, supporting tools, and communication
strategies
Analytics Workforce
development
Strengthen regulatory
management of
manufacturing variations
13 Develop and implement risk-based programs to incorporate
post-marketing manufacturing variations into marketing
authorizations
Analytics
System
development
aThese recommendation types were defined by the authors to classify how the recommendations might be implemented:
Analytics – Generating and interpreting data collected through the implementation of activities and general research
Collaboration – Coordinating and communicating within and among NRAs, their stakeholders and other technical partners
System development – Establishing processes, procedures and platforms to enhance and facilitate activities
Workforce development – Building the capacity of staff
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were those we felt were the highest priority and most
likely to lead to sustainable positive change to global
regulatory systems.
The information in Table 2 was collected through in-
formal discussions with NRA staff, consultants, and
other technical experts.
Implement value-added regulatory practices that utilize
available resources
Advance and leverage convergence and reliance initiatives
As the globalization of pharmaceutical manufactur-
ing continues, NRAs struggle to individually regulate
existing and new medical products [11]. An effective
way to tackle this challenge is to continue advancing
the adoption of workable regulatory reliance models,
while leveraging complementary convergence efforts.
Regulatory reliance refers to a sovereign authority
using the work products of trusted authorities and
organizations to inform a regulatory decision based
on local settings and their own scientific knowledge,
knowledge of the local health care system and cul-
ture, and regulatory procedures (see Fig. 1) [12, 13].
Regulatory convergence, complementarily, entails
country regulatory processes and technical require-
ments becoming more aligned over time [14]. Imple-
mentation of reliance initiatives will differ by
regulatory functions (e.g., registration vs. pharmacov-
igilance) and will need to be tailored so should take
into account available resources and the previous
work and experience of other NRAs [15, 16].
Table 2 Financing mechanism for selected NRAsa
Country (NRA) Structure Funding
Source(s)
Comments
Argentina (Administración Nacional de
Medicamentos Alimentos y Tecnología)
Autonomous Government
funds
Administratively and financially independent but user fees
go to central funding; decision-making is independent.
Australia (Therapeutic Goods Administration) Autonomous User fees Regulatory decisions are made by delegates of the Ministry
of Health (TGA employees)
Ethiopia (Food and Medicine and Health Care
Administration and Control Authority)
Semi-autonomous Government
funds
User fees
Under Department of Health but reports to Parliament
Ghana
(Food and Drugs Authority)
Operationally
autonomous
(not financially)
Government
funds
User fees
Does not sit under the Ministry of Health; independent
agency that reports to the Minister
India (Drug Controller General of India,
Drug Control Authority)
Semi-autonomous,
under Ministry of Health
Government
funds
Minimal user fees, which are unsustainable and provided
to the Ministry
Indonesia (Badan Pengawas Obat dan
Makanan)
Ministry level institution Government
funds
Minimal user fees; head of BPOM is a minister-level position,
reports to President
Lao People’s Democratic Republic
(Food and Drug Department)
Not autonomous,
under Ministry of Health
Government
funds
Donors
Netherlands
(Medicines Evaluation Board)
Autonomous User fees Regulatory decisions are independent of Ministry
Pakistan
(Drug Regulatory Authority Pakistan)
Autonomous Government
funds
User fees
Under Ministry of Health but independent in its decision-
making; minimal government funding (~ 2%)
Papua New Guinea (Pharmaceutical Service
Standards Branch)
Not autonomous, under
Department of Health
Government
funds
Fees are returned to Treasury
Singapore
(Health Sciences Authoritya)
Autonomous, under
Ministry of Health
Government
funds
User fees
Statutory board under Ministry of Health, autonomy in
decision-making
South Africa (South African Health Products
Regulatory Authority)
Autonomous, under the
Department of Health
Government
funds
User fees
Independent public entity that retains revenue generated,
employs its own staff, and is accountable to Parliament
United States of America
(Food and Drug Administration)
Autonomous, under
Department of Health
and Human Services
Government
funds
User fees
Fee proportions varies by centers; decisions made almost
exclusively by civil servants in FDA
(delegated decision-making by law and regulation)
Zimbabwe (Medicines Control Authority
of Zimbabwe)
Autonomous, not
under Ministry of Health
User fees Not under Ministry of Health, but Minister is responsible
for actions
aHealth Products Regulation Group
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Document and communicate current reliance and convergence
efforts and develop supporting infrastructure and tools to
facilitate implementation
Investment is needed to further document and communi-
cate the status of current reliance and convergence efforts.
These efforts are occurring in many regions, e.g., − the
East African Community, the Zazibona initiative (a collab-
oration among several countries of the Southern African
Development Community), and the Caribbean Commu-
nity [6, 12, 17]. However, the work of these types of initia-
tives is often poorly documented and communicated. We
believe the broader global health community needs to be
better informed about these efforts. One mechanism for
improved communication is to develop a public database
hosted by WHO and populated by regulators and their
technical partners. Existing reliance and convergence ef-
forts should be identified, and data on who is leading the
work, where it is taking place, the intended objectives, and
current status should be listed. This should be an integral
part of WHO’s Coalition of Interested Partners (CIP), an
initiative spearheaded by WHO seeking to achieve better
coordination, efficiency and outcomes in regulatory sys-
tem strengthening activities, and Good Reliance Practices
initiatives [18]. It would enable stakeholders and other
regions to better determine how they might engage in
these activities, adapt their approaches based on existing
best practices, and avoid duplicating efforts. Complement-
ing this external collaboration is the need for a clear defin-
ition of the roles and responsibilities of all departments
and institutions that form the regulatory system within a
given country to avoid ambiguity and unnecessary com-
plexity. In addition, we recommend the development of
infrastructure and systems to continue operationalizing
reliance as a twenty-first century regulatory best practice
[11, 12, 19]. For example, a simple, modular, open-source
platform that allows collation and simultaneous review of
public assessment reports and confidential data sharing
should be available. Its architecture should be adaptable,
and administration of the platform should be simple and
preserve the integrity of needed confidentiality and the de-
cision-making process of NRAs.
Strengthen capacity building networks
Workforce development, along with developing a pipe-
line for the next generation of regulatory scientists, con-
tinues to be an invaluable factor in advancing
value-added regulatory processes, including reliance ef-
forts. Historically, the focus of many training efforts was
Access and review public assessment reports (e.g. US FDA redacted reports, 
European Public Assessment Reports (EPARS), WHO PARS and PIRS)
Public data from mature regulators assessment reports is reviewed by the NRA to reach a preliminary 
decision. To complement this, investment should support the development of a federated database with all 
public assessment reports that are pulled through machine learning and can collectively be searched and 
filtered.P
A
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Request redacted information from applicant or NRA
The NRA then requests information redacted from the public assessment reports from the 
manufacturer who has submitted the application or from an NRA who has already registered the 
product. This redacted information can include detailed proprietary manufacturing information, as 
well as other commercially sensitive details. Alternatively, request unredacted reports with the 
application.A
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Request region/country specific information
In addition to redacted information, if needed, the NRA solicits regional or sub-population 
specific information, epidemiological data or comorbidity landscape data.
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Prepare and evaluate abridged assessment report
Collating the information below, the NRA puts together an abridged assessment 
report that is tailored to the country where the applicant is seeking to register the 
product. The assessment report should be made public to enable neighbors to utilize 
this information in their decision-making 
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Approve marketing authorization / variation locally
Based on the collective package of information (appropriate common technical 
document  (CTD) modules, assessment reports, redacted information, regional 
specific information), the NRA, in communication with technical partners where 
appropriate, approves or does not approve the medical product for marketing 
within a specified timeframe after receiving the informationA
P
P
R
O
V
A
L
Receive common technical document modules in marketing application 
If reliance is going to occur, the local NRA needs to have the underlying CTD common data modules as 
reference, when needed, during the reliance-based review of assessment and inspection reports. These modules 
should be the same as those submitted to WHO Prequalification or a trusted authority on which reliance will be 
based.
C
T
D
 R
E
C
E
IP
T
Fig. 1 Operationalizing regulatory reliance for registration of medical products
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based on how well-resourced NRAs approach their re-
sponsibilities, but such approaches are often inappropriate
and impractical in low-resource settings. Curricula that
focus on the specific capacities needed by LMIC regula-
tors are lacking (e.g., oversight of local manufacturing,
regulation through reliance and networks, local
post-marketing activities, and management of regulatory
administrative functions). Inconsistent training quality
and uncoordinated training initiatives also limit the tech-
nical capacity of different regulators. WHO is working to
address this by developing a global curriculum framework
that will complement its global benchmarking tool (GBT)
and define the requisite competencies for regulatory staff
working across the different regulatory functions [20].
Investment is needed to (1) strengthen partnerships, such
as WHO’s CIP [18], that are working to coordinate and
ensure greater consistency and appropriate focus of cap-
acity building efforts, and (2) strengthen training and
technical assistance providers associated with networks
such as the International Pharmaceutical Regulators
Programme, the International Council for Harmoniza-
tion’s Training Subcommittee, Asia-Pacific Economic
Cooperation’s (APEC) Centers of Excellence, select aca-
demic institutions and leading regulatory agencies such as
the African Medicines Regulatory Harmonization Initia-
tive’s Regional Centres of Regulatory Excellence [17].
WHO and these institutions grasp the specific technical
needs and regulatory goals of the NRAs they support and,
when working together, can deliver appropriately focused,
competency-based capacity building programs in a sus-
tainable, coordinated, and effective manner.
Institutionalize sustainability
NRAs are generally funded through a mix of taxes, user
fees, and occasionally donors, such as the Global Fund to
Fight AIDS, Tuberculosis and Malaria or the United States
Agency for International Development Table 2 provides
information on the financing mechanism of 14 illustrative
NRAs that represent varying regulatory maturity levels, in-
come classifications, and geographic regions. Many LMICs
cannot adequately fund all of their public health needs and
their NRAs are particularly vulnerable [17, 21, 22]. Defining
clear goals and institutionalizing sustainability in terms of
human and financial resources is therefore essential for
effective long-term NRA functioning [7]. Sustainability
ensures that the necessary processes and resources exist to
enable the NRA to fulfill its mandate while remaining
responsive, value-added, outcome-oriented, science-based,
accountable, risk-proportionate, and independent [11]. To
ensure this, any external investments should focus on
supporting the development of infrastructure, strategies,
systems, and staff rather than directly funding NRA oper-
ational activities.
Define needed capacities in NRAs using the WHO
global benchmarking tool
As part of a continuous improvement process and in line
with WHA Resolution 67.20, WHO has begun beta-testing
and finalizing its harmonized medicines-vaccines GBT. The
GBT uses an agreed-upon set of standards, indicators, and
metrics that cover the enabling regulatory system and all of
the major regulatory function modules. These standards
have been published by WHO as factsheets, which act as
rubrics to allow NRAs, WHO, and selected technical
partners to assess an NRA’s maturity level (see Fig. 2)
[23]. WHO and other technical partners have per-
formed formal benchmarking of 17 countries and 39
additional countries have performed self-assessments
[24]; 28 LMICs remain to be benchmarked. Once com-
pleted, these assessments need to be used to set realistic
goals, identify barriers for NRAs to meet their regulatory
functioning goals, define specific investment needs, and
determine future capacity needs as more complex prod-
ucts and supply chains come to their markets. Plans to
publicize NRAs reaching higher maturity levels as “WHO
IS
O
 9
00
4
Can be considered as functional if rely on other 
regulators for some specific functions
Stable formal system 
approach
Continual improvement 
emphasizedNo formal approachReactive approach
Evolving national regulatory 
system that partially performs 
essential regulatory functions 
Stable, consistently well-
functioning and integrated 
regulatory system
Regulatory system operating at 
advanced level of performance 
and continuous improvement
Some elements of regulatory 
system exist
Target of 
WHA Resolution 67.20
Advanced/reference 
regulators
1 2 3 4
Fig. 2 WHO global benchmarking tool maturity levels. Adapted with permission from the WHO NRA Regulatory System Strengthening Database [24]
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listed-authorities” (currently stringent regulatory author-
ities) [25] following GBT assessment by WHO, will also
help promote trust, reliance, and transparency.
Establish stable and transparent financing
mechanisms
NRAs must ensure they have the legal mandate, political
will, and related structures to properly finance operations,
specifically through revenue generation and retention.
The generation and retention of revenue means that an
NRA requires less direct government funding and
strengthens functional efficiency and accountability
(Table 3). While many NRAs in LMICs levy fees, they
often charge arbitrary amounts that do not cover their
value-added activities. This can create barriers to both
market entry and adequate post-marketing quality surveil-
lance, circumvent reliance efforts, and hinder potential fi-
nancial sustainability [11, 26, 27]. The African Union (AU)
Model Law on Medical Product Regulation (Model Law)
provides a reference guide to assist countries to review or
enact laws with powers to levy, collect, and utilize fees for
rendered services [28]. Once established, the legal
mandate needs to be supported by the development of an
appropriate, transparent and process-oriented fee struc-
ture commensurate with the regulatory workload re-
quired. These efforts should also be accompanied by
support for the development of an institutional develop-
ment plan that is based on the GBT assessment and pro-
vides a blueprint for an NRA to reach and maintain its
desired maturity level and to establish systems that ensure
efficient and risk-based management of human, financial
and information technology resources [4, 23].
Utilize risk-based approaches for resource allocation
NRA financial and human resources should not be divided
equally among all regulated products and regulatory pro-
cesses [11, 13]. In LMICs, where available resources are
rarely close to commensurate with the needs and expecta-
tions of the NRA, adoption of a risk-based approach for
resource allocation is crucial [11, 30]. A risk-based ap-
proach seeks to channel available resources to regulatory
functions and activities that are most likely to facilitate
access to quality-assured products and identify and
address high-risk quality problems (e.g., a falsified
anti-tuberculosis medicine), thereby maximizing the im-
pact of regulatory investments [30, 31]. Generally, such ac-
tivities include oversight of country clinical trials and
manufacturing, country post-marketing pharmacovigi-
lance and quality surveillance, and supply chain security.
Moreover, these are typically activities that an agency can-
not rely on other agencies to implement.
Perform risk analysis and implement risk
management
Investment and technical assistance are needed to
support NRAs in performing an initial risk analysis and
subsequently implementing risk management activities.
A risk analysis uses quantitative and qualitative methods
to describe the risks in a system. It includes analyzing
the pharmaceutical market, specific country characteris-
tics and the regulatory environment, and it seeks to as-
certain attributes that increase (risk triggers) or decrease
(risk-mitigating factors) the probability of risk occurrence
(Fig. 3) [30, 32]. Risk estimation then calculates the prob-
ability and magnitude of each identified risk and ranks
them commensurately with available resources. Because
of required data needs and environmental familiarity, the
best analyses are those that involve all relevant stake-
holders, encourage dialogue, and proactively seek to iden-
tify critical product quality issues [30, 33]. The results of a
risk analysis can then inform risk management activities
such as the actual allocation of resources (e.g., financial,
human, infrastructural) to regulatory functions based on
their risk ranking [30]. This can include, for example, the
reallocation of staff from pre-marketing to post-marketing
quality surveillance and pharmacovigilance functions.
Develop systems to monitor and evaluate the
impact of risk-based approaches for resource
allocation
The final phase of investment needs to be directed to-
wards the development of systems that monitor and
evaluate the impact of risk-based approaches for RSS [30,
31]. Impact metrics can include health outcomes, costs
and cost savings, efficiency, and sustainability. Risk-based
approaches need to be agile, adaptable, and responsive.
They should evolve based on the acquisition of new data
Table 3 The Medicines Control Authority of Zimbabwe (MCAZ)
– An example of sustainable, risk-based regulation
Due to a policy shift, in 1997, several Zimbabwean government entities,
including MCAZ, were given the ability to run their operations by utilizing
revenue generated through the provision of services. Since this change,
MCAZ has performed several financial analyses and exercises to balance
the need to cover the cost of service provision and the need to enable
market entry for both domestic and international manufacturers. Equally
important to obtaining the legal authority to independently run its operations
was the work MCAZ undertook to develop the infrastructure and processes
required to operationalize this new process: establishing the necessary
financial procedures, developing standard operating procedures, and hiring
and training an internal finance, accounting, and operations team.
Because MCAZ are funded through generated fees, senior leadership also
quickly recognized that a risk-based approach would be the only way to
regulate effectively, balancing the need to sustain activities with the criticality
of protecting patient safety. An example of this can be seen in how the
organization has approached the regulation of medical devices. While MCAZ
has had the mandate to regulate medical devices since its inception, the
Authority decided to roll out this regulation based on risk, which dictated an
initial focus on male condoms in 2005 and medical gloves in 2006 because of
the prevalence of HIV/AIDS at the time. With the recent publication of WHO’s
model guidelines on the regulation of medical devices [29], MCAZ is again
displaying its responsiveness by starting to regulate the import and export
of additional medical devices as part of an initial risk analysis.
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(e.g., medical product safety surveillance data) and situ-
ational changes (e.g., disease outbreaks, conflict). There-
fore, ongoing monitoring and evaluation of the allocation
of resources based on risk needs to be institutionalized to
identify and respond to these catalytic factors and measure
the effectiveness of the approach itself. Regulators need to
understand and develop the skills required to design and
implement monitoring and evaluation systems, including
impact evaluation programs to gather and utilize data to
inform decision-making, prompt regulatory action, and
achieve maximum public health impact.
Timely access to new quality-assured medical products
Strengthen registration efficiency and timeliness
Registration/marketing authorization is the procedure
whereby an NRA independently assesses the safety, effi-
cacy, and quality of a medical product and then gives per-
mission for legal marketing in a given jurisdiction [34].
Many LMICs will facilitate myriad drug and vaccine intro-
ductions in the coming years [35]. New medical products,
including biologics, similar biotherapeutic products
(SBPs), medical devices, and vaccines offer health benefits
for patients [6]. However, many factors, including the
growing number of products seeking registration, their
manufacturing complexity, limited evaluation expertise,
and the specific regulatory systems required for these
products result in an extended backlog for product intro-
duction in many LMICs [6, 19, 36].
Establish and refine value-added registration
processes, resources, and systems
To regulate new products and help ensure their accessibil-
ity, the existence of a value-added, product-class specific
registration process is a critical and necessary step. These
processes must be science-based, transparent, account-
able, and predictable. Registration requirements for
medical devices, for example, differ from those of other
medical products partly because their scope, risk, and
complexity vary greatly. A 2015 study in Africa reported
that the majority of countries assessed did not have a
registration procedure in place for in vitro diagnostics
(IVDs) [37]. Registration procedures for devices should
therefore follow the guidance of the International Medical
Device Regulators Forum (IMDRF) and WHO, both of
which recommend that registration of a new medical de-
vice be based on a four-tiered risk classification scheme
[29, 38]. To support this scheme, existing regional and
international resources and systems need to be proactively
adapted and implemented in LMICs. An example of this,
would be to continue to evolve the WHO Prequalification
(PQ) Programme to include new classes of medicines,
such as biologics (which has been initiated), medical de-
vices beyond IVDs, and other essential medicines [7]. Do-
nors should also invest in further strengthening functional
technical regional harmonization initiatives (RHIs). Once
NRAs and RHIs have demonstrated a sufficient and sus-
tainable maturity level (level 3 and 4 in Fig. 2), WHO
should recognize their assessment for the purpose of pre-
qualification, as it does now with several mature regulatory
authorities. Complementing these efforts is the need to de-
velop and adopt/adapt regulations; related data standards;
and functional, fit-for-purpose, robust information man-
agement systems (IMS) that address and support the spe-
cific manufacturing quality needs of many of these highly
complex products, such as SBPs [19, 39].
Build value-added technical capacity of assessors
Registration of new products requires a cadre of trained
and competent assessors, who evaluate registration
packages and have knowledge of emerging and existing
products, knowledge many LMICs lack [11]. Resources
such as existing training platforms, best practices, and
Politics and governance
Border porosity
Country Characteristics
Supply side (e.g. local manufacturers)
Demand side (e.g. burden of disease)
Characteristics of the Medical 
Products Market
Regulatory capabilities and framework
Human resources and infrastructure
Characteristics of the Regulatory 
and QA Environment
ImpactRisk Analysis
Risk 
Management 
(Resource 
Allocation)
Fig. 3 Risk analysis and implementation workflow. Adapted with permission from A Framework for Risk-Based Resource Allocation for Pharmaceutical
Quality Assurance for Medicines Regulatory Authorities in Low- and Middle-Income Countries [30]
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procedures, need to continue to be made available to facili-
tate value-added capacity building for assessors by experi-
enced institutions and networks as discussed in
recommendation 2 [7, 17, 40]. It is critical to determine
what capabilities are needed at the LMIC level, recognizing
that one size does not fit all, to ensure that assessors can re-
view manufacturing dossiers for new products. If products
are locally manufactured, the ability to oversee manufactur-
ing in an NRA’s own jurisdiction is a necessary competence.
Conversely, if products are imported after having been
inspected by a mature NRA or the PQ programme, regulat-
ing through reliance on inspection reports and assessments
is needed. Likewise, if products are going to be assessed
through a regional network or a work-sharing mechanism,
the capacity to regulate through and in networks is a skill
set that needs to be developed. Building such competencies
through a coordinated, specific, goal-focused initiative, such
as WHO’s CIP, is highly encouraged.
Strengthen inspection capacity and effectiveness
The inspection of facilities involved in product develop-
ment and along the supply chain is integral to assure the
quality of medical products. Inspections conducted in ac-
cordance with international standards, norms, and guide-
lines reveal weaknesses and deficiencies as well as actual or
predictable errors in production, quality control, storage, or
distribution [41]. The complexity and number of new and
generic medical products entering LMICs results in in-
creased pressure on already strained local inspectorates that
need to identify staff with the relevant expertise to decide
when such inspections are needed and whether physical or
desk-based (reliance) inspections are most appropriate [7].
Enhance information sharing and use and reliance
on existing inspection resources
To strengthen inspection capacity, information sharing
(such as the ability to share full inspection reports among
agencies) needs to continue to improve and existing re-
sources need to be utilized effectively. Using these re-
sources and guidelines, such as those published by the
Pharmaceutical Inspection Cooperation Scheme (PIC/S),
can prevent duplication of efforts and conserve resources,
provided local inspectors have access to unredated inspec-
tion reports, and the skills to interpret the information
therein. Mature authorities should share complete (i.e.,
unredacted) inspection reports, strive for mutual recogni-
tion of inspections, and promote work sharing and more
coordination [11, 22, 42]. Mutual recognition of inspec-
tion reports was formalized between the U.S. FDA and
European Medicines Agency (EMA) at the end of 2017,
although this has been standard practice between EMA
and Australia, Canada, Japan, Switzerland, and others for
a while [43]. Furthermore, the IMDRF has successfully
piloted a Medical Device Single Audit Program, which will
promote reliance and reduce work load for inspection of
medical devices [44]. Support is therefore needed to con-
tinue the development and adaption of processes required
for LMICs to embed reliance (reduction) and recognition
(replacement) [13], including through the sharing of
manufacturing inspection information, into their own
regulatory processes. This will enable more prudent and
risk-based allocation of scarce resources to perform phys-
ical inspections of those facilities that have not been
inspected and that manufacturer’s use for LMIC markets.
Build capacity of multi-disciplinary teams of
inspectors
Support is needed to build and train multi-disciplinary
teams of inspectors with relevant expertise to inspect facil-
ities in local jurisdictions. Training topics should include:
assurance of good distribution practices locally, reviewing
of external public and unredacted inspection reports, and
risk-based post-manufacturing inspection of facilities in
the product supply chain. Inspectorates in regions with
limited capacity and significant local manufacturing
should receive support to obtain PIC/S membership; spe-
cifically, this could be for a member state from each of
Africa’s Regional Economic Communities where, apart
from South Africa, there are no PIC/S participating au-
thorities (Table 4). Investment is also needed to develop
internal training plans and programs to ensure that exist-
ing staff are continuously learning to meet the challenges
of a changing environment and that new staff acquire the
knowledge and skills needed to perform their functions.
Training implementation should utilize existing platforms,
resources, and tools, such as the PIC/S Inspectorates’
Academy, WHO PQ training or secondment opportun-
ities and joint inspections [45].
Limited evidence-based data to support post-marketing
regulatory action
Develop and implement risk-based post-marketing quality
surveillance systems
Post-marketing quality surveillance (PMQS) is the process
of routinely sampling and testing medical products in a
planned, value-added schema, following their market
approval. As a regulatory function, risk-based PMQS com-
plements traditional pharmacovigilance activities, generat-
ing data on product quality to identify supply chain
vulnerabilities and highlight product quality issues in the
local market (see Table 5). However, current regulatory
systems in many LMICs are not equipped to develop and
implement effective and sustainable PMQS systems and
consequently cannot generate and utilize the data required
to support needed regulatory actions [6, 11, 21]. This is
due, in some situations, to limited recognition of the value
of PMQS as a critical regulatory function, and a lack of
practical, tailored guidance and tools [11, 46].
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Establish recognition of the value of risk-based
post-marketing quality surveillance throughout
the supply chain
PMQS is often undervalued as a regulatory function, par-
ticularly in LMICs where limited resources cannot be de-
ployed equally across all functions and are typically
allocated to pre-market functions, such as registration
[46]. For example, while the AU Model Law indicates that
an NRA “may” institute PMQS, it specifies that a national
pharmacovigilance program “shall” be established [28].
Local NRAs therefore need support to engender recogni-
tion of the value of developing and implementing PMQS
systems. Pre-market activities cannot identify local supply
chain disruptions, cold chain excursions, illicit trafficking,
or poor distribution practices that lead to product degrad-
ation. While pharmacovigilance can be a valuable identi-
fier of quality problems with attendant patient harm, its
focus is principally on adverse events, such as adverse
drug reactions. PMQS is one of the most patient-centered
regulatory functions, monitoring product quality issues
immediately prior to their use by patients. As such, its im-
plementation is as central as registration, inspection, or
pharmacovigilance.
Develop and implement risk-based post-marketing
quality surveillance programs, supporting tools,
and communication strategies
Once recognition of the value of PMQS is established,
investment needs to focus on developing programs using
well-established guidelines, tools, and best practices, tai-
lored to country contexts [46, 47]. Passive systems for
reporting of suspected quality issues should also be
established. The program design needs to take into ac-
count the local pharmaceutical sector, scope of sampling,
governance and transparency, laboratory and personnel
capacity development requirements, coordination, com-
munication, financing, and sustainability [46]. Comple-
menting the design of PMQS programs is the need to
continue to examine available and emerging technolo-
gies that can be used for advanced analytical screening
[4, 17, 48, 49]. Investment is then needed to support the
implementation of PMQS activities in LMICs, notably
sampling following a validated methodology, testing in
internationally accredited laboratories, and the subsequent
appropriate dissemination, communication, and use of
data to support appropriate regulatory action. The pro-
gram design should also identify key stakeholders and
their roles and responsibilities, and outline targeted advo-
cacy and training priorities, such as strengthening of na-
tional quality control laboratories. Beyond training,
Table 4 South Africa – The road to Pharmaceutical Inspection
Cooperation / Scheme (PIC/S) membership
The South African Health Products Regulatory Authority (SAHPRA), formerly
the Medicines Control Council, was invited to join PIC/S in July 2007 –
a first for an African country. PIC/S support to NRAs focuses on strengthening
their inspectorates by harmonizing good manufacturing practices (GMP)
standards and processes for inspection of quality systems, promoting
networks and information exchange with other NRAs, and supporting training
and capacity building of GMP inspectors. South Africa’s process for PIC/S
membership began with application in 1997.
A key step in enabling this process was ensuring buy-in and support of all
stakeholders, including government and industry. Legislative amendments
to the Medicines Act were passed in 2003 to further strengthen licensing
arrangements for the manufacturing, import, export, wholesaling, and
distribution of medicines. During the application process, the NRA reviewed
its existing procedures to identify areas of improvement. The NRA designed
and implemented a quality management system that incorporated a
quality manual, technical guidelines, and standard operating procedures
for all inspection activities, highlighting confidentiality, code of conduct,
ethics, and conflict of interest. Improving the capacity of the inspectorate
also focused on strengthening administrative, structural, and technical
components. Through a series of workshops held between 2004 and 2006,
local industry was engaged to adopt the new PIC/S GMP guidelines and
ensure their effective implementation, compliance, and enforcement.
This process was supported by local technical experts as well as experts
from PIC/S member countries to ensure a common interpretation and
understanding of the technical principles by both inspectors and industry.
Removing barriers to effective communication and encouraging transparency
and feedback were key to ensuring the support and compliance of industry
stakeholders.
In September 2006, PIC/S inspectors assessed the NRA’s progress and made
several observations, which were addressed, resulting in admission the following
year as PIC/S′ 31st Participating Authority. SAHPRA continues to strengthen its
regulatory capacity by tapping into the pool of PIC/S expertise. PIC/S
membership has provided opportunities for networking with counterpart NRAs;
promoting quality systems and participating in Joint Visit Programmes,
Expert Circles, subcommittees, and working groups.
Table 5 Therapeutic Goods Administration – Risk-based post-
marketing quality surveillance as a critical regulatory function
Australia’s NRA, the Therapeutic Goods Administration (TGA), has been
100% cost recovered (autonomous, but self-funded) since the late 1990s.
Cost-recovery compels the organization to think strategically about the
implementation of its regulatory functions. In 2011, TGA assessed its testing
program, identified areas of improvement, and set a roadmap for investing
in and establishing a risk-based PMQS program for its programmed testing
activities. Risk management standards were consulted and adapted to
TGA’s context, principles were identified (e.g., the program would need to be
dynamic, iterative, and responsive to change), and a framework and related
foundational processes were developed (e.g., risk analysis, risk management,
impact evaluation, risk communication).
The program took 3 years to develop, primarily because of the complexity
of designing a system that would cater to and enable risk scoring of all
product categories (e.g. over-the-counter medicines, complementary
medicines, and medical devices). The program has now been active for
several years and, importantly, publishes testing data through TGA’s
website. Products that undergo a more intensive pre-market assessment
(e.g. prescription medicines), tend to score lower and are therefore tested
less frequently. However, groups within categories can be scored differently.
For example, both vaccines and biological medicines are regulated as
prescription medicines in Australia but score more highly than other
prescription medicines in general. This is due to the increased complexity
of the products and increased complexity of manufacturing; in the case of
vaccines, it is also because they are given to an entire cohort of healthy
children every year. The risk category of a product can also be elevated
(a dynamic program) in response to specific factors, such as poor GMP,
failed laboratory testing results, or adverse event reports.
Key to the success of the program was political will and staff commitment,
which enabled the development and implementation processes to be followed
thoughtfully and have led to less resource waste, increased effectiveness
(e.g., shifting the type of products that are tested), and identification of
poor-quality products.
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support is needed for the development of local and re-
gional databases that complement WHO’s Global Surveil-
lance and Monitoring System [50]. Data standards that
define how quality control data are collected and stored
are urgently needed as are procedures that identify the
practical aspects of communicating results, sharing infor-
mation, and initiating enforcement action.
Strengthen regulatory management of manufacturing
variations
Develop and implement risk-based programs to incorporate
post-marketing manufacturing variations into marketing
authorizations
During the lifecycle of an approved medical product,
changes to the authorized manufacturing process are inev-
itable. Whether to improve manufacturing efficiency,
utilize new manufacturing technologies, move physical lo-
cations of manufacturing facilities, or change suppliers of
manufacturing components, assessing and authorizing
these variations to the marketing authorization for the
product require regulatory agency focus, resources, and
specific knowledge [51]. In many LMICs, these resources
and knowledge are often not available. Because of this,
manufacturing variations are often backlogged, resulting
in shortages when a product manufactured in compliance
with the still current authorization in a country is no lon-
ger available. Investment in the development of local pro-
cesses and systems that rely on the approval of variations
by the WHO PQ Programme or mature NRAs could have
a significant impact on continued quality product avail-
ability, provided the variation authorized was for the spe-
cific product that is being shipped to the country.
Conclusion
The globalization of medical product manufacturing
means no single regulatory authority alone can guaran-
tee the safety of all products in its country’s market [9,
11]. In today’s linked supply chains, medical product
quality and safety in one country increasingly depends
on systems in other countries. Strengthening medical
product regulatory systems in LMICs in value-added
ways enables reliance and work sharing and fosters a co-
ordinated approach as a part of the drive for universal
access to quality healthcare [6, 42]. The recommenda-
tions identified herein, if implemented, can increase
timely access to quality-assured medical products and
improve detection of and response to SF medical prod-
ucts. The recommendations focus on advancing reliance
and regulatory networking efforts, institutionalizing sus-
tainability, utilizing risk-based approaches, enhancing
value-added registration and inspection capacity, and de-
veloping systems for the generation of data to support
post-marketing regulatory action. Our intent is for this
paper to be used as a blueprint to help guide the next
wave of investment in RSS in order to realize the aspir-
ational but universally agreed-upon Sustainable Develop-
ment Goal of good health and wellbeing for all [52].
Endnotes
1For the purposes of this article, the definition of access
encompasses physical accessibility (availability within rea-
sonable reach of those who need them), financial afford-
ability (ability to pay without financial hardship), and
acceptability (willingness to seek medical products when
needed) [1].
2For the purposes of this article, the definition of medical
products includes medicines, biologics, vaccines, and med-
ical devices.
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